开放合作的资产

双特异性抗体资产

双特异性抗体（BsAbs）是一类经过工程改造的抗体，能够同时结合两个不同的抗原或表位。与单克隆抗体或联合用药相比，双特异性抗体具备新的功能特性，展现出更高的疗效、更低的耐药性以及更广泛的适用范围。同时，其毒性有望低于联合使用的单抗疗法。因此，双特异性抗体被视为新一代抗体治疗手段。
  • 10+
    全人双抗资产
  • 10+
    类TCR抗体资产
获取数据包 预定会议
相关资源

在此页面上

  • 为什么选择百奥赛图的双抗产品组合？
  • 开放合作的双抗/多抗资产
  • 部分资产概览
  • FAQs

网络研讨会

查看全部

    海报

    查看全部

      为什么选择百奥赛图的双抗产品组合？

      • 该抗体由百奥赛图专有的RenLite小鼠平台生产，具有人类类似的多样化重链序列库。
      • RenLite产生的双抗具有高亲和力和高特异性。
      • 双抗涵盖多个疾病领域，包括肿瘤学、炎症和自身免疫。
      • 全人双抗已在体内测试中展现出优异的可开发性和疗效。
      • 我们提供多种合作模型，包括双抗的许可、转让和共同开发，并与许多行业领先者建立了合作伙伴关系。

      开放合作的双抗/多抗资产

      Format Therapeutic Area Product Number Target(s) Immunization
      • Development
      • Hits
        selection         Leads
        selection         Candidate
        selection
      		Preclinical IND Phase I Status
      BsAb Oncology YH008 PD-1 x CD40
      		Partnered ex-China rights available
      BsAb Oncology YH006 OX40 x CTLA4
      BsAb Oncology BCG021 4-1BB x CD40
      BsAb Inflammation and Autoimmunity BCG028 OX40 x OX40
      BsAb Oncology - CD40 x CTLA4
      BsAb Oncology BCG051 GDF15 x VEGFA
      BsAb Inflammation and Autoimmunity - IL4RA x KIT
      BsAb Inflammation and Autoimmunity - IL13 x TSLP
      BsAb Inflammation and Autoimmunity - IL17A x IL17F x IL4RA
      BsAb Oncology - B7-H3 x FN1
      TCE Oncology - CD28 x CDH17 x CD3e
      TCE Oncology - STEAP1 x CD3e
      Tri-Ab Oncology BCG024 DLL3 x CD3E x 4-1BB
      Tri-Ab Oncology BCG038 EGFR x VEGFA x CD98
      Tri-Ab Oncology - PD-L1 x CD98 x VEGFA
      Tri-Ab Inflammation and Autoimmunity - C2 x FCGRT x ALB
      Tri-Ab Oncology - PD-L1 x IL11 x VEGFA
      Tri-Ab Oncology - PD-L1 x VEGFA x IL27R

      部分资产概览

      此外，百奥赛图还拥有用于组装与CD3结合的双特异性抗体的类TCR抗体（TCR mimic）资产。联系我们，探索评估/许可/共同开发机会！

      4-1BB x CD40 （BCG021）全人双抗用于肿瘤学
      资产亮点：
      • 具有条件性4-1BB和CD40激动活性，需在双靶点交联的情况下才能发挥作用
      • 在体内表现出强效抗肿瘤活性，并在与抗PD-1单抗联合使用时显著增强肿瘤生长抑制效果
      • 理想的理化性质
      • 在小鼠中表现良好的安全性
      • 在小鼠体内表现出抗体样分子的药代动力学特征
      • 专利申请已提交

      Frequently Asked Questions (FAQs) About Bispecific Antibody Assets

      1. What therapeutic assets are available in Biocytogen’s bispecific antibody pipeline?

      Biocytogen’s pipeline includes bispecific antibodies (BsAbs), biparatopic antibodies (BpAbs), and trispecific antibodies (Tri-Abs), including diverse T-cell engager (TCE) programs. These assets span oncology, inflammation and autoimmunity, and metabolism, with more than 10 preclinical programs ready for out-licensing or partnership.

      2. What preclinical data packages are available for Biocytogen’s bispecific antibody assets?

      Depending on the program, Biocytogen’s preclinical BsAb assets are supported by data packages covering binding affinity, specificity, in vitro functional activity, in vivo efficacy in disease mouse models, PK, safety, and developability. For TCE assets, additional data include target-dependent T-cell activation and proliferation, in vitro cytotoxicity or tumor-lysis activity, and cytokine-release assessments.

      3. How does Biocytogen aim to expand the therapeutic window of next-generation T-cell engagers (TCEs) for solid tumors?

      Biocytogen designs next-generation T-cell engagers (TCEs) to expand the therapeutic window—balancing effective tumor killing at doses that remain safe and tolerable. Our approach combines tuned CD3 engagement with localized co-stimulation including 4-1BB or CD28 to sustain antitumor activity while limiting systemic immune activation and cytokine release syndrome (CRS) risk.
      For example, Biocytogen’s BCG024, a DLL3 × CD3ε × 4-1BB trispecific TCE, integrates a spatially restricted CD3 scFv with a fully human 4-1BB VHH co-stimulatory module. Preclinical findings show potent cytotoxicity with limited systemic cytokine induction, supporting its potential for a wider therapeutic window.

      4. Are Biocytogen’s bispecific antibody programs available for licensing or co-development?

      Yes. Biocytogen welcomes flexible collaboration opportunities for evaluation, licensing, technology transfer, and co-development. Partners can request program-specific data packages and discuss collaboration options aligned with their development priorities. Contact us today!

      5. What development stages does Biocytogen’s bispecific antibody pipeline cover?

      Biocytogen’s bispecific antibody portfolio spans early discovery, preclinical and clinical development. Many preclinical assets have advanced to candidate selection, and the partnered YH008 program has progressed into Phase I.
      For early-stage programs, Biocytogen offers TAA antibody binders and backbones to support customized BsAb development.